New drug cocktail tested for Tough-to-Treat leukemia in frail patients
NCT ID NCT04964505
Summary
This early-stage study tested the safety of combining three drugs—uproleselan, azacitidine, and venetoclax—for older adults or those too frail for standard intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The goal was to find a safe dose and see if this combination could effectively kill cancer cells. The study was small and terminated early, focusing primarily on side effects and dosing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.